10 years ago

Desktop Genetics Secures Investment from Illumina for CRISPR Gene Editing Platform

  • Desktop Genetics, a London-based software company focused on CRISPR gene editing technology, received an investment from Illumina, a global leader in next-generation sequencing (NGS) technology

  • The investment will be used to fund the continued development and commercialization of the DESKGEN platform, with a particular focus on integration with NGS pipelines

  • The company is working with recognized leaders in the gene editing field, including Editas Medicine, Horizon Discovery, Transcriptic, and enEvolv.

      • ProblemHealthcare

      "Desktop Genetics aims to simplify the process of designing, purchasing, and executing CRISPR gene editing experiments, enabling researchers to conduct these experiments without needing their own specialist laboratories."

      Solution

      "The company has developed the DESKGEN platform, a system that supports the design, construction, management, and purchase of DNA, reagents, and services crucial in gene editing and molecular biology."

      Covered on